Drug Trial Radar · NCT06447779
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25,000
Planned (sponsor's estimate)
Start
Jul 13, 2024
Primary completion
Mar 29, 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- MAXVAX Biotechnology Limited Liability CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
Conditions
- Herpes Zoster
Interventions
Recombinant Zoster Vaccine (CHO Cell)Biological
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
NaCl solution PlaceboBiological
0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and olderTime frame: 30 days after the last vaccination
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hebei Provincial Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, China
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
Yunnan Center For Disease Control and Prevention
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.